PA MSSP PMA Enhanced
Jeff Mandel
ACO Primary Contact
202-803-7979
Location
Location

Aledade Primary Care ACO LLC
4550 Montgomery Ave, Ste 950
Bethesda, MD 20814
 

ACO Participants ACO Participant in Joint Venture
Penn Medicine-PMA N

Member First Name Member Last Name Member Title/Position Member's Voting Power (Expressed as a percentage) Membership Type Practice Legal Business Name
MARK BROWN Board Member 7.5 ACO Participant Representative

Penn Medicine-PMA

JONATHAN BUSSENGER Board Member 7.5 ACO Participant Representative

Penn Medicine-PMA

CHRIS DIDOMENICO Board Member/Medicare Beneficiary Representative 12.5 Medicare Beneficiary Representative

Penn Medicine-PMA

JOEL EISNER Board Member 7.5 ACO Participant Representative

Penn Medicine-PMA

LEROY FLEISCHER Board Member/ACO Medical Director 7.5 ACO Participant Representative

Penn Medicine-PMA

JEFF MANDEL Board Member/Chair 12.5 Other Aledade
MANJULA RAMAN Board Member 7.5 ACO Participant Representative

Penn Medicine-PMA

KARL SCHWABE Board Member/Compliance Committee Lead 7.5 ACO Participant Representative

Penn Medicine-PMA

ROY SCHWARTZ Board Member 7.5 ACO Participant Representative

Penn Medicine-PMA

CHARLES SCHWARTZ Board Member 7.5 ACO Participant Representative

Penn Medicine-PMA

JILLIAN WAWRZYNIAK Board Member 7.5 ACO Participant Representative

Penn Medicine-PMA

YORK YANG Board Member 7.5 ACO Participant Representative

Penn Medicine-PMA

  • Executive Director: Dr. Jeff Mandel
  • Medical Director: Leroy Fleischer
  • Compliance Officer: Ms. Amy Youtz
  • Quality Assurance/Improvement Officer: Emily Maxson

Committee Name Committee Leader Name 
Compliance Committee Karl Schwabe / Compliance Committee Leader

Networks of individual practices of ACO professionals. 

 

  • Third Agreement Period

    • Performance Year 2021, $ 9,245,805

    • Performance Year 2020, $ 7,731,029

  • Second Agreement Period

    • Performance Year 2019, $0

  • First Agreement Period

    • Performance Year 2018, $0
    • Performance Year 2017, $0
    • Performance Year 2016, $0
    • Performance Year 2015, $0

 

Third Agreement Period

  • Performance Year 2021
    • Proportion invested in infrastructure: 20%
    • Proportion invested in redesigned care processes/resources: 30%
    • Proportion of distribution to ACO participants: 50%
  • Performance Year 2020
    • Proportion invested in infrastructure: 10%
    • Proportion invested in redesigned care processes/resources: 35%
    • Proportion of distribution to ACO participants: 55%
2021 CMS WEB INTERFACE QUALITY PERFORMANCE RESULTS:
Measure #
Measure Name
Rate
ACO Mean
Measure #: 1
Diabetes: Hemoglobin A1c (HbA1c) Poor Control2
20.70
12.46
Measure #: 134
Preventative Care and Screening: Screening for Depression and Follow-up Plan
89.46
74.38
Measure #: 236
Controlling High Blood Pressure
77.02
74.87
Measure #: 318
Falls: Screening for Future Fall Risk
94.14
87.03
Measure #: 110
Preventative Care and Screening: Influenza Immunization
82.50
80.52
Measure #: 226
Preventative Care and Screening: Tobacco Use: Screening and Cessation Intervention
27.27
80.97
Measure #: 113
Colorectal Cancer Screening
77.54
73.63
Measure #: 112
Breast Cancer Screening
70.77
75.11
Measure #: 438
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease
81.75
84.24

Please note, the Quality ID #: 370 Depression Remission at 12 months quality measure is not included in public reporting due to low sample size.


For Previous Years’ Financial and Quality Performance Results, Please Visit data.cms.gov.

Payment Rule Waivers
FRAUD AND ABUSE WAIVERS